Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines

Ramucirumab is approved both as monotherapy and in combination with Paclitaxel for advanced gastric cancer in patients with disease progression after chemotherapy. In tumor cells, the VEGFA-VEGFR2 binding activates autocrine survival and migration signaling in angiogenesis independent manner. The pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-04, Vol.10 (1), p.7162, Article 7162
Hauptverfasser:	Refolo, Maria Grazia, Lotesoriere, Claudio, Lolli, Ivan Roberto, Messa, Caterina, D’Alessandro, Rosalba
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase 13/1 13/2 13/95 14 14/34 38 38/77 631/67/1504/1829 692/699/67/1504/1829 82 82/80 AKT protein Angiogenesis Antibodies, Monoclonal, Humanized - pharmacology Autocrine signalling Cancer therapies Cell cycle Cell growth Cell Line, Tumor Cell migration Chemotherapy Combined treatment Drug interaction Drug Synergism Gastric cancer Gene Expression Regulation, Neoplastic - drug effects Humanities and Social Sciences Humans Immunotherapy MAP kinase MAP Kinase Signaling System - drug effects Mesenchyme Molecular modelling Monoclonal antibodies Motility multidisciplinary Neoplasm Proteins - biosynthesis Paclitaxel Paclitaxel - agonists Paclitaxel - pharmacology Ramucirumab Science Science (multidisciplinary) Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - pathology Targeted cancer therapy TOR protein Tumor cell lines Tumor cells Tumorigenicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!